Literature DB >> 21133333

International stem cell tourism and the need for effective regulation. Part II: Developing sound oversight measures and effective patient support.

Cynthia B Cohen1, Peter J Cohen.   

Abstract

Part I of this article, published in the March 2010 issue of the Kennedy Institute of Ethics Journal, traces and addresses the provision of unproven stem cell treatments in Russia and India, examines the concept of innovative treatment, and concludes that stronger regulations are needed to protect the health and informed choices of patients. The current paper, Part II, proposes that the regulatory frameworks for the development of safe and efficacious treatments in effect in the United States and the United Kingdom provide examples of strong oversight measures from which countries seeking to obtain international credibility for their biotechnological competence could draw when developing regulations for stem cell treatments. Major sources of information available to persons who consider receiving such unproven treatments are explored in order to understand and address their concerns. The paper concludes with proposed measures to inform those considering the pursuit of unproven stem cell treatments abroad more accurately about their efficacy and safety and provide them with improved medical and social support in their home countries.

Entities:  

Mesh:

Year:  2010        PMID: 21133333     DOI: 10.1353/ken.2010.0001

Source DB:  PubMed          Journal:  Kennedy Inst Ethics J        ISSN: 1054-6863


  2 in total

1.  Navigating physicians' ethical and legal duties to patients seeking unproven interventions abroad.

Authors:  Jeremy Snyder; Krystyna Adams; Y Y Chen; Daniel Birch; Timothy Caulfield; I Glenn Cohen; Valorie A Crooks; Judy Illes; Amy Zarzeczny
Journal:  Can Fam Physician       Date:  2015-07       Impact factor: 3.275

Review 2.  What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury?

Authors:  Robert A Watson; Trevor M Yeung
Journal:  BMC Neurol       Date:  2011-09-23       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.